Avadel Pharmaceuticals (AVDL) Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVDL shares.
View AVDL analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 1 year target prices for Avadel Pharmaceuticals' shares. Their AVDL share price forecasts range from $5.00 to $20.00. On average, they predict the company's stock price to reach $13.44 in the next twelve months. This suggests that the stock has a possible downside of 6.7%.
View analysts price targets for AVDL or view top-rated stocks among Wall Street analysts.

Avadel Pharmaceuticals' stock was trading at $7.16 at the start of the year. Since then, AVDL stock has increased by 101.1% and is now trading at $14.40.
View the best growth stocks for 2023 here.

Avadel Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 3,350,000 shares, a drop of 13.9% from the April 30th total of 3,890,000 shares. Based on an average daily trading volume, of 916,600 shares, the days-to-cover ratio is presently 3.7 days.
View Avadel Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our AVDL earnings forecast.

Avadel Pharmaceuticals plc (NASDAQ:AVDL) posted its quarterly earnings data on Thursday, March, 30th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.14.

ETFs with the largest weight of Avadel Pharmaceuticals (NASDAQ:AVDL) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Nasdaq Future Gen 200 ETF (QQQS), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB),

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Avadel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Gendell Jeffrey L (6.83%), Wealth Effects LLC (3.22%), Brandes Investment Partners LP (1.86%), Samsara BioCapital LLC (1.82%), Renaissance Technologies LLC (1.06%) and Bank of America Corp DE (0.89%). Insiders that own company stock include Eric J Ende, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish and Thomas S Mchugh.
View institutional ownership trends.

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVDL stock can currently be purchased for approximately $14.40.

Avadel Pharmaceuticals (NASDAQ:AVDL) has a market capitalization of $1.11 billion and generates $22.33 million in revenue each year. The company earns $-137,460,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis.

Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The official website for the company is www.avadel.com. The company can be reached via phone at (531) 901-5201, via email at investors@avadel.com, or via fax at 353-1526-1077.